霍奇金淋巴瘤 中国就医指南

Hodgkin lymphoma (HL) is a distinct type of B-cell-derived hematologic malignancy characterized by the presence of diagnostic Reed-Sternberg cells within a reactive inflammatory microenvironment. Unlike non-Hodgkin lymphomas, HL exhibits highly stereotyped histopathology and predictable clinical behavior, typically presenting with painless, progressive lymphadenopathy—most commonly in cervical or supraclavicular regions. The disease is classified into two main subtypes: classical Hodgkin lymphoma (cHL), accounting for over 95% of cases, and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), a rarer, indolent variant with different biology and management. Pathogenesis involves malignant transformation of germinal center or post-germinal center B lymphocytes, driven by genetic alterations (e.g., chromosome 9p24.1 amplification leading to PD-L1/PD-L2 overexpression), Epstein-Barr virus (EBV) infection in ~30–50% of cases (especially in endemic or immunocompromised populations), and dysregulated immune surveillance. Chronic inflammation, cytokine signaling (e.g., NF-κB, JAK/STAT), and tumor–microenvironment crosstalk further support survival and proliferation of Reed-Sternberg cells. Epidemiologically, HL displays a bimodal age distribution—peaking in young adults aged 20–34 years and again in individuals over 55—suggesting differing etiologic drivers across age groups. Globally, incidence ranges from 2–3 cases per 100,000 persons annually, with higher rates in high-income countries. In China, age-standardized incidence is approximately 0.5–0.8 per 100,000, though underdiagnosis and regional variability persist. Established risk factors include EBV seropositivity, HIV infection, autoimmune conditions (e.g., rheumatoid arthritis, celiac disease), family history (particularly monozygotic twins), and socioeconomic factors linked to delayed diagnosis. Quality of life (QoL) impact is substantial and multifaceted: early-stage patients often experience fatigue, night sweats, pruritus, and unexplained weight loss (‘B symptoms’), while treatment-related toxicities—including chemotherapy-induced neuropathy, infertility, secondary malignancies (e.g., AML, breast cancer), cardiovascular damage from mediastinal radiation, and persistent anxiety—significantly impair physical functioning, emotional well-being, and social engagement. Survivorship care increasingly emphasizes longitudinal monitoring, psychosocial support, fertility preservation, and lifestyle interventions to mitigate long-term morbidity. With modern risk-adapted therapy—including ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) or AVD regimens, PET-guided response assessment, and emerging immunotherapies like brentuximab vedotin and checkpoint inhibitors—5-year overall survival exceeds 90% for early-stage and 75–85% for advanced-stage disease in high-resource settings. However, disparities in access to diagnostics, staging imaging (PET/CT), and specialized hematologic oncology care remain critical barriers to optimal outcomes in many regions of China.

# 霍奇金淋巴瘤治疗方案与费用明细（血液科）

一、非手术/药物/保守治疗方案

适用人群：初治Ⅰ–Ⅱ期（早期）、Ⅲ–Ⅳ期（晚期）、老年或合并症患者。

• •ABVD方案（标准一线）：多柔比星+博来霉素+长春碱+达卡巴嗪，6–8周期

- 血常规/肝肾功/心电图/肺功能检查：¥350–¥800/次（每周期前）

• •AVD方案（博来霉素禁忌者）：¥10,500–¥25,000/周期
• •PD-1单抗（如信迪利单抗）联合化疗（高危/复发）：¥28,000–¥42,000/周期（含输注费）

二、放疗方案（根治性辅助）

适用条件：Ⅰ–Ⅱ期伴大包块、放疗敏感亚型（如结节硬化型）

• •受累野放疗（ISRT）：30–36 Gy，15–18次

- 模拟定位+CT/MRI融合计划：¥2,200–¥4,500

三、特殊复杂方案

• •自体造血干细胞移植（ASCT）（复发/难治）：

• •BV（维布妥昔单抗）+PD-1联合方案（CD30+耐药）：¥45,000–¥68,000/周期

四、方案快速选择指南

• •预算有限初治患者：优选国产ABVD+公立三甲放疗（总约¥8–15万）
• •年轻高危/复发者：ASCT为首选根治路径（医保报销后自付约¥8–12万）
• •≥65岁或心肺功能差者：减量化AVD+密切监测（年均¥4–7万）